

## FLT1

### Recombinant Human VEGFR-1 / Fc Chimera, soluble

<b>Catalog No.</b>	CRF105A CRF105B	<b>Quantity:</b>	10 µg 50 µg
<b>Alternate Names:</b>	Vascular Endothelial Growth Factor Receptor-1, Fms-like tyrosine kinase 1, FLT-1		
<b>Description:</b>	<p>Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 was fused with the Fc part of human IgG<sub>1</sub>. The recombinant mature sVEGFR-1<sub>D1-7</sub>/Fc is a disulfide-linked homodimeric protein. The soluble receptor protein consists of all 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding.</p> <p>Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF<sub>165</sub> to VEGFR-2 is dependent on heparin.</p>		
<b>UniProt ID:</b>	P17948		
<b>Gene ID:</b>	2321		
<b>Source:</b>	Insect cells		
<b>Molecular Weight:</b>	130 kDa, (954 aa) monomer		
<b>Formulation:</b>	Lyophilized from PBS, pH 7.4.		
<b>Purity:</b>	> 90%, by SDS-PAGE and visualized by silver stain		
<b>Endotoxin Level:</b>	< 0.1 EU/µg		
<b>Biological Activity:</b>	The activity of sVEGFR-1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells.		
<b>Reconstitution:</b>	<b>Centrifuge vial prior to opening.</b> The lyophilized sVEGFR-1/Fc is soluble in water and most aqueous buffers. The lyophilized sVEGFR-1/Fc should be reconstituted in PBS or medium to a concentration ≥ 50 µg/ml.		
<b>Storage &amp; Stability:</b>	Lyophilized samples are stable for greater than six months at -20°C to -80°C. Reconstituted sVEGFR-1/Fc should be stored in working aliquots at -20°C to -80°C. <b>Avoid repeated freeze-thaw cycles.</b>		

**Amino Acid Sequence:** SKLKDPELSL KGTQHIMQAG QTLHLQCRGE AAHKWSLPPEM VSKESEERLSI  
TKSACGRNGK QFCSTLTLNT AQANHTGFYS CKYLAVPTSK KKETESAIYI  
FISDTGRPFV EMYSEIPEII HMTGRELVI PCRVTSPNIT VTLKKFPLDT LIPDGKRIIW  
DSRKGFIIISN ATYKEIGLLT CEATVNGHLY KTNYLTHRQT NTIIDVQIST PRPVKLLRGH  
TLVLNCTATT PLNTRVQMTW SYPDEKNKRA SVRRRIDQSN SHANIFYSVL  
TIDKMQNKDK GLYTCRVRSG PSFKSVNTSV HIYDKAFITV KHRKQQVLET  
VAGKRSYRLS MKVKAFPSPE VVWLKDGLPA TEKSARYLTR GYSLIHKDVT  
EEDAGNYTIL LSIKQSNVFK NLTATLIVNV KPQIYEKAVS SFPDPALYPL GSRQILTCTA  
YGIPQPTIKW FWHPCNHNHS EARCDFCSNN EESFILDADS NMGNRIESIT  
QRMAIIIEGKN KMASTLVVAD SRISGIYICI ASNKVGTVGR NISFYITDVP  
NGFHVNLEKM PTEGEDLKLS CTVNKFLYRD VTWILLRTVN NRTMHYSISK  
QKMAITKEHS ITLNLTIMNV SLQDSGTYAC RARNVYTGEE ILQKKEITIR  
DQEAPYLLRN LSDHTVAISS STTLDCHANG VPEPQITWFK NNHKIQQEPG  
IILGPGSSTL FIERVTEEDE GVYHCKATNQ KGSVESSAYL TVQGTRSDKT  
HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV  
KFNWYVDGVE VHNATKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV  
SNKALPAPIE KTISKAKGQP REPQVYTLPP SREEMTKNQV SLTCLVKGFY  
PSDIAVEWES NGQPENNYKT TPPMLDSDGS FFLYSKLTVD KSRWQQGNVF  
SCSVMHEALH NHYTQKSLSL SPGK

**NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**



**Cell Sciences®**  
65 Parker Street  
Unit 11  
Newburyport, MA 01950

Toll Free: 888-769-1246  
Phone: 978-572-1070  
Fax: 978-992-0298

E-mail: [info@cellsciences.com](mailto:info@cellsciences.com)  
Website: [www.cellsciences.com](http://www.cellsciences.com)